Sustained response to single agent therapy with continuous lenalidomide in a pre-treated high-risk multiple myeloma patient

摘要

In multiple myeloma cells, particular genomic alterations, such as dell7p, are considered to be associated with higher-risk disease. However, in recentyears, the introduction of tha-lidomide, bortezomib and lenalidomide has substantially enriched the therapeutic armamentarium for both newly diagnosed and relapsed multiple myeloma patients with poor prognosis. We describe the case of such a patient (female, 60 3?ears of age), who refused autologous stem cell transplantation and became refractory to an induction therapy with bortezomib. Subsequently, she did not tolerate a regimen containing thalidomide and therefore was started on maintenance therapy with ienalidomide. After 4 years of treatment, the patient still is in partial remission. Our case demonstrates the long-term efficacy and good tolerability of lenalidomide monotherapy in a pre-treated high-risk multiple myeloma patient. An individually adjusted dose of lenalidomide may be a good option for patients with refractory disease who are unable to tolerate or refuse to undergo autologous stem cell transplantation.